242 related articles for article (PubMed ID: 21188213)
1. Her-2/neu testing and therapy in gastroesophageal adenocarcinoma.
Moelans CB; van Diest PJ; Milne AN; Offerhaus GJ
Patholog Res Int; 2010 Dec; 2011():674182. PubMed ID: 21188213
[TBL] [Abstract][Full Text] [Related]
2. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.
Bang YJ
J Clin Gastroenterol; 2012 Sep; 46(8):637-48. PubMed ID: 22751336
[TBL] [Abstract][Full Text] [Related]
3. Pathologic diagnostics of HER2 positivity in gastroesophageal adenocarcinoma.
Koopman T; Louwen M; Hage M; Smits MM; Imholz AL
Am J Clin Pathol; 2015 Feb; 143(2):257-64. PubMed ID: 25596252
[TBL] [Abstract][Full Text] [Related]
4. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
Hechtman JF; Polydorides AD
Arch Pathol Lab Med; 2012 Jun; 136(6):691-7. PubMed ID: 22646280
[TBL] [Abstract][Full Text] [Related]
5. HER2 testing in gastric cancer.
Albarello L; Pecciarini L; Doglioni C
Adv Anat Pathol; 2011 Jan; 18(1):53-9. PubMed ID: 21169738
[TBL] [Abstract][Full Text] [Related]
6. HER2 testing in gastric and gastroesophageal adenocarcinomas.
Vakiani E
Adv Anat Pathol; 2015 May; 22(3):194-201. PubMed ID: 25844677
[TBL] [Abstract][Full Text] [Related]
7. HER2 Oncogene Amplification and Immunohistochemical Profiling in Gastric Adenocarcinoma.
Raj N; Verma D; Kumar A; Rai P; Rao RN
Discoveries (Craiova); 2018 Dec; 6(4):e83. PubMed ID: 32309603
[No Abstract] [Full Text] [Related]
8. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of HER-2/neu Gene Amplification in Epithelial Ovarian Carcinoma.
Pankaj S; Kumari J; Choudhary V; Kumari A; Kumari S; Kumari A; Nazneen S; Madhawi R; Kumar S
J Obstet Gynaecol India; 2019 Oct; 69(Suppl 2):177-181. PubMed ID: 31686753
[TBL] [Abstract][Full Text] [Related]
10. HER2 Testing in Gastric/Gastroesophageal Junction Adenocarcinomas: Unique Features of a Familiar Test.
Ross JS; Mulcahy M
Gastrointest Cancer Res; 2011 Mar; 4(2):62-6. PubMed ID: 21673877
[TBL] [Abstract][Full Text] [Related]
11. HER2 Expression in Gastric and Gastroesophageal Cancer: Report from a Tertiary Care Hospital in North India.
Tewari M; Kumar A; Mishra RR; Kumar M; Shukla HS
Indian J Surg; 2015 Dec; 77(Suppl 2):447-51. PubMed ID: 26730043
[TBL] [Abstract][Full Text] [Related]
12. Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy.
Diaz NM
Cancer Control; 2001; 8(5):415-8. PubMed ID: 11579337
[TBL] [Abstract][Full Text] [Related]
13. How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?
Lorenzen S; Lordick F
Curr Opin Oncol; 2011 Jul; 23(4):396-402. PubMed ID: 21505336
[TBL] [Abstract][Full Text] [Related]
14. Quantitative real-time PCR assay with immunohistochemical evaluation of HER2/neu oncogene in breast cancer patients and its correlation with clinicopathological findings.
Gheni N; Westenberg D
Indian J Pathol Microbiol; 2020 Feb; 63(Supplement):S123-S128. PubMed ID: 32108644
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
16. Targeted HER2 treatment in advanced gastric cancer.
Jørgensen JT
Oncology; 2010; 78(1):26-33. PubMed ID: 20185938
[TBL] [Abstract][Full Text] [Related]
17. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
[TBL] [Abstract][Full Text] [Related]
18. A survival guide to HER2 testing in gastric/gastroesophageal junction carcinoma.
Subasinghe D; Acott N; Kumarasinghe MP
Gastrointest Endosc; 2019 Jul; 90(1):44-54. PubMed ID: 30928424
[TBL] [Abstract][Full Text] [Related]
19. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing.
Rüschoff J; Dietel M; Baretton G; Arbogast S; Walch A; Monges G; Chenard MP; Penault-Llorca F; Nagelmeier I; Schlake W; Höfler H; Kreipe HH
Virchows Arch; 2010 Sep; 457(3):299-307. PubMed ID: 20665045
[TBL] [Abstract][Full Text] [Related]
20. Current Targeted Therapies in HER2-Positive Gastric Adenocarcinoma.
Curea FG; Hebbar M; Ilie SM; Bacinschi XE; Trifanescu OG; Botnariuc I; Anghel RM
Cancer Biother Radiopharm; 2017 Dec; 32(10):351-363. PubMed ID: 29265917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]